drugset / Trial / NCT04788407
Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts
Phase 4
Unknown
456 enrolled
Fundación Huésped
Laboratorios Roemmers S.A.I.C.F. · collabMinisterio de Salud de Ciudad Autónoma de Buenos Aires · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The primary objective of this study is to evaluate the efficacy of the drug nitazoxanide 500 mg, administered three times a day, in relation to placebo in preventing the development of COVID-19 in household contacts of patients diagnosed with the disease.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2022-04-30
- Completion
- 2022-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nitazoxanide | Other / unclassified | 500 mg | — |